ALK Abello reports underlying growth for first half of 2015

ALK Abello has announced its financial results for the first half of 2015, during which it achieved an underlying revenue growth rate of four percent.

The company's revenue total for the six-month period came to 565 million Danish kroner (361.68 million pounds), with base business growth of one percent recorded in local currency terms.

Though overall financial performance was impacted by lower milestone payments compared to last year, it was able to achieve a number of key goals in the development of its lead product candidate, the HDM SLIT-tablet.

Regulatory reviews of the drug continue to progress in Europe and Japan, with the first launches expected to take place in 2016. A regulatory filing for the tablet has also been submitted in Australia.

ALK now expects to grow revenue in the base business by three to five percent across 2015 in local currency terms, up from its previous guidance range of zero to five percent. The figure is expected to be in the range of 2.3 billion to 2.35 billion kroner.